Data gathered: February 1
Alternative Data for Ventyx Biosciences
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 75 | Sign up | Sign up | Sign up |
| Webpage traffic | 2,000 | Sign up | Sign up | Sign up |
| Employee Rating | 20 | Sign up | Sign up | Sign up |
| Google Trends | 6 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 2 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,558 | Sign up | Sign up | Sign up |
| Twitter Mentions | 11 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | N/A | Sign up | Sign up | Sign up |
| Linkedin Employees | 88 | Sign up | Sign up | Sign up |
About Ventyx Biosciences
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases.
| Price | $2.01 |
| Target Price | Sign up |
| Volume | 1,120,000 |
| Market Cap | $145M |
| Year Range | $1.72 - $5.28 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
 |
JPMorgan Chase & Co. Buys 20,236 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)January 22 - ETF Daily News |
|
HC Wainwright Has Strong Forecast for VTYX FY2024 EarningsJanuary 18 - ETF Daily News |
|
FY2029 Earnings Estimate for VTYX Issued By HC WainwrightJanuary 18 - ETF Daily News |
|
Ventyx Biosciences (NASDAQ:VTYX) Given “Neutral” Rating at HC WainwrightJanuary 16 - ETF Daily News |
|
Ventyx Biosciences Discloses Preliminary 2024 Financials and Pipeline StrategyJanuary 15 - ETF Daily News |
Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor PortfolioJanuary 13 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 0 | 7.9M | -7.9M | -35M | -38M | -0.500 |
| Q2 '24 | 0 | 7.9M | -7.9M | -32M | -35M | -0.450 |
| Q1 '24 | 0 | 8M | -8.1M | -39M | -41M | -0.620 |
| Q4 '23 | 1.1M | 11M | -11M | -47M | -50M | -0.790 |
| Q3 '23 | 0 | 8.2M | -8.2M | -54M | -58M | -0.920 |
Insider Transactions View All
| Nuss John filed to sell 464,582 shares at $2.4. December 30 '24 |
| Gujrathi Sheila filed to buy 130,000 shares at $2.3. December 26 '24 |
| Nuss John filed to sell 485,701 shares at $2.3. December 19 '24 |
| Mohan Raju filed to buy 2,175,028 shares at $2. November 25 '24 |
| Mohan Raju filed to buy 1,913,276 shares at $1.8. November 25 '24 |
Similar companies
Read more about Ventyx Biosciences (VTYX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter mentions, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Ventyx Biosciences?
The Market Cap of Ventyx Biosciences is $145M.
What is the current stock price of Ventyx Biosciences?
Currently, the price of one share of Ventyx Biosciences stock is $2.01.
How can I analyze the VTYX stock price chart for investment decisions?
The VTYX stock price chart above provides a comprehensive visual representation of Ventyx Biosciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Ventyx Biosciences shares. Our platform offers an up-to-date VTYX stock price chart, along with technical data analysis and alternative data insights.
Does VTYX offer dividends to its shareholders?
As of our latest update, Ventyx Biosciences (VTYX) does not offer dividends to its shareholders. Investors interested in Ventyx Biosciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Ventyx Biosciences?
Some of the similar stocks of Ventyx Biosciences are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.